PROGRAM OVERVIEW
Join us for a dynamic, expert-led broadcast exploring the latest clinical data for EXDENSUR, the first and only ultra-long-acting asthma biologic given as 1 dose every 6 months. This unique session features a panel of leading specialists and clinical investigators across disciplines: Dr Eric Caplan (Allergy/Immunology) and Dr Stella Cohen (Pulmonology), as they share their perspectives on the opportunity for EXDENSUR to change clinical practice. You will also have the opportunity to engage and ask the panel questions during the Q&A session.
PROGRAM OBJECTIVES
- Hear perspectives on how this multi-disciplinary panel navigates patient challenges when managing severe eosinophilic asthma with a biologic
- Discuss the safety and efficacy data from clinical trials evaluating exacerbation reduction in patients with severe asthma with an eosinophilic phenotype aged 12 years and older
- Explore how EXDENSUR was designed for extended dosing of 1 dose every 6 months
Broadcast Schedule
The broadcast will be available at various times throughout the day and evening, depending on your time zone. Reference the chart below for a complete list of broadcast times.
This broadcast is available via webcast and teleconference at the times listed below.
Available via
Lunch Program: Wednesday, January 28, 2026
| EASTERN | CENTRAL | MOUNTAIN | PACIFIC |
|---|---|---|---|
| 12:15 PM | 11:15 AM | 10:15 AM | 9:15 AM |
| 1:15 PM | 12:15 PM | 11:15 AM | 10:15 AM |
| 2:15 PM | 1:15 PM | 12:15 PM | 11:15 AM |
| 3:15 PM | 2:15 PM | 1:15 PM | 12:15 PM |
Dinner Program: Thursday, January 29, 2026
| EASTERN | CENTRAL | MOUNTAIN | PACIFIC |
|---|---|---|---|
| 7:00 PM | 6:00 PM | 5:00 PM | 4:00 PM |
| 9:00 PM | 8:00 PM | 7:00 PM | 6:00 PM |
Intended Audience
This broadcast is intended for US healthcare professionals involved in the treatment of severe asthma.
Indication
EXDENSUR is indicated for the add-on maintenance treatment of severe asthma, characterized by an eosinophilic phenotype, in adult and pediatric patients aged 12 years and older. EXDENSUR is not indicated for the relief of acute bronchospasm or status asthmaticus.
Important Safety Information
Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis, can occur following administration of EXDENSUR. If a hypersensitivity reaction occurs, discontinue EXDENSUR and initiate appropriate therapy.
Acute Asthma Symptoms or Deteriorating Disease EXDENSUR should not be used to treat acute asthma symptoms or acute exacerbations.
Risk Associated with Abrupt Reduction of Corticosteroid Dosage Upon initiation of EXDENSUR therapy, do not abruptly discontinue systemic or inhaled corticosteroids. Reductions in corticosteroid dose, if appropriate, should be gradual and under the supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.
Parasitic (Helminth) Infection Patients with pre-existing helminth infections should be treated for their infection prior to initiation of EXDENSUR therapy. If patients become infected while receiving EXDENSUR and do not respond to anti-helminth treatment, discontinue EXDENSUR until the infection resolves.
Adverse Reactions In patients receiving EXDENSUR, the most common adverse reactions (≥4%) were upper respiratory tract infection, allergic rhinitis, influenza, arthralgia, and pharyngitis. Injection site reactions have also occurred.
USE IN SPECIFIC POPULATIONS The data in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Transport of endogenous IgG antibodies and monoclonal antibodies, such as depemokimab-ulaa, across the placenta increases as pregnancy progresses and peaks during the third trimester.
EXDENSUR can cross the placenta during pregnancy and the presence of the YTE modification may prolong and increase exposure to the infant exposed in utero. The impact of transmission to the fetus should be considered. Pregnant women exposed to EXDENSUR, or their healthcare providers, should report EXDENSUR exposure by calling 1-888-825-5249.
To report SUSPECTED ADVERSE REACTIONS, contact GSK at https://gsk.public.reportum.com or 1-888-825-5249 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
|
|
Trademarks are property of their respective owners. ©2025 GSK or licensor. PMUS-DEPEWCNT250020 December 2025 Produced in USA. |